This is a summary of the European public assessment report (EPAR) for Nexavar. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nexavar.
Therapeutic Indication
### Therapeutic indication **Hepatocellular carcinoma** Nexavar is indicated for the treatment of hepatocellular carcinoma. **Renal cell carcinoma** Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. **Differentiated thyroid carcinoma** Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Therapeutic Area (MeSH)
N/AATC Code
L01EX02
ATC Item
sorafenib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| sorafenib | N/A | 索拉非尼 |
EMA Name
Nexavar
Medicine Name
Nexavar
Aliases
N/ANo risk management plan link.
